Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

NCT05934526 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

390

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG: Placebo
DRUG: Seralutinib
DEVICE: Generic Dry Powder Inhaler

Sponsor

GB002, Inc.